Subscribe

Jan ter Meulen, MD, PhD

Articles by Jan ter Meulen, MD, PhD

Van ter Meulen, MD, PhD

Developing Controllable Tumor Infiltrating Lymphocyte Therapies

ByJan ter Meulen, MD, PhD

June 17th 2022

Jan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.

Latest Updated Articles

Trending on CGTlive®

Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis

CGTLive®’s Weekly Rewind – October 31, 2025

Quarter Century Update: Thoughts on Reducing Costs of Goods

Quarter Century Update: Future Predictions for the Field

© 2025 MJH Life Sciences^®

All rights reserved.